MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "MAO-B inhibitors"

  • 2019 International Congress

    Safinamide in the treatment of URINARY symptoms in PARKinson’s disease (SURINPARK)

    A. Gómez López, I. Pareés Moreno, S. Fanjul Arbós, JL. López Sendon, JC. Martínez Castrillo, A. Alonso Cánovas (Madrid, Spain)

    Objective: We compared the effects of safinamide on the urinary symptoms of Parkinson's disease with other therapies. Background: Urinary symptoms (US) are common, disabling and…
  • 2019 International Congress

    Is safinamide helpful in multiple system atrophy?

    R. Simões, A. Gonçalves, JJ. Ferreira (Lisboa, Portugal)

    Objective: To retrospectively review the clinical benefit of safinamide in patients with Multiple System Atrophy. Background: Safinamide is a new monoamine oxidase-B inhibitor, with dopaminergic…
  • 2019 International Congress

    Can Safinamide Help to Stabilize Dopaminergic Treatment in Parkinson’s Disease?

    B. Solano Vila, A. Cots Foraster, M. Montserrat Roses (Girona, Spain)

    Objective: After more than two years of clinical experience with safinamide  we want to retrospectively review its utility as a levodopa saver in our Parkinson's…
  • 2019 International Congress

    High dose off-label Safinamide treatment in Young Onset Parkinson’s Disease patients

    C. Carrarini, M. Russo, F. Barbone, F. Dono, M. Rispoli, M. Onofrj, A. Thomas (Chieti, Italy)

    Objective: To assess tolerability and efficacy of high dose Safinamide treatment in Young Onset Parkinson’s Disease (YOPD) patients with dystonia and history of impulse controls…
  • 2018 International Congress

    Safinamide in Parkinson’s disease

    G. Martí-Andrés, R. Jiménez-Bolaños, J. Arbelo-González, J. Pagonabarraga-Mora, C. Duran-Herrera, M. Carmona-Abellán, R. Luquin-Puido (Pamplona, Spain)

    Objective: To evaluate clinical effects, safety and tolerability of safinamide add-on levodopa in Parkinson’s disease (PD) patients. Background: Safinamide is a recently approved adjunctive treatment…
  • 2018 International Congress

    Efficacy and safety of Rasagiline in treatment of gait disturbances in dementia with Lewy bodies

    A. Chimagomedova, O. Levin, M. Anikina, I. Ayzenberg (Moscow, Russian Federation)

    Objective: We aimed to investigate the efficacy and safety of rasagiline in addition to levodopa in patients with dementia with Lewy bodies (DLB). Background: Management…
  • 2018 International Congress

    Safinamide add-on therapy increases ON time without dyskinesia in fluctuating Parkinson’s Disease (PD) patients with moderate to severe dyskinesia

    V. Tubazio, C. Cattaneo, E. Bonizzoni, C. Keywood (Bresso (Milan), Italy)

    Objective: This post-hoc analysis examined safinamide efficacy for providing dyskinesia-free ON time in LID patients. Background: Safinamide has both dopaminergic and glutamate modulating activity. The…
  • 2018 International Congress

    Evaluation of the interaction between safinamide and opicapone in Parkinson’s disease patients with fluctuations

    J. Garcia-Caldentey, MA. Prats-Sedano, I. Legarda-Ramirez, E. Estelrich-Peyret, B. Vives-Pastor, PJ. Garcia (Palma de Mallorca, Spain)

    Objective: To describe and to evaluate a Balearic ongoing Parkinson's disease (PD) Project to evaluate the efficacy and tolerance of the interaction between safinamide and…
  • 2018 International Congress

    Safinamide effect in patients with Parkinson’s disease and deep brain stimulation

    F. Mancini, A. Di Fonzo, G. Lazzeri, L. Borellini, V. Silano, M. Lacerenza, C. Comi (Milan, Italy)

    Objective: Aim of this retrospective study is to evaluate safety and efficacy of safinamide in the treatment of motor complications in patients with Parkinson’s Disease…
  • 2018 International Congress

    Use of safinamide: A clinical practice review of 2 year experience

    C. Borrue-Fernandez (San Sebastian Reyes, Spain)

    Objective: Review the clinical use, efectivity and side efects in a population based cohort. Background: Safinamide is an oral, once a day adjunctive therapy for…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley